Mirum Pharmaceuticals 과거 순이익 실적
과거 기준 점검 0/6
Mirum Pharmaceuticals 의 수입은 연평균 -17.2%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 56.6%의 비율로 증가해 왔습니다.
핵심 정보
-17.20%
순이익 성장률
0.33%
주당순이익(EPS) 성장률
| Biotechs 산업 성장률 | 17.04% |
| 매출 성장률 | 56.64% |
| 자기자본이익률 | -329.43% |
| 순이익률 | -140.24% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 18
MIRM: 2026 PSC Readout Will Reshape Long Term Earnings Outlook
Analysts have raised their average price target for Mirum Pharmaceuticals from about $140 to roughly $177, citing updated assumptions around revenue growth, higher profit margins, and a slightly lower discount rate in their models. Analyst Commentary Bullish analysts have been steadily lifting their price targets on Mirum Pharmaceuticals, pointing to what they see as solid execution, supportive guidance, and a healthy pipeline of potential catalysts.Seeking Alpha • May 12
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise
Summary Mirum Pharmaceuticals is evolving into a rare disease commercialization platform with multiple late-stage assets and robust commercial execution. MIRM raised 2026 net product sales guidance to $660–$680M, reflecting strong visibility and momentum, especially from LIVMARLI and bile acid products. The BlueJay acquisition and late-stage programs in HDV, PSC, and FOP create a catalyst-rich period, supporting the premium valuation versus sector peers. I see MIRM as a high-growth, catalyst-driven mid-cap biotech with sufficient cash reserves and a platform poised for multiple product launches. Read the full article on Seeking Alpha
내러티브 업데이트 • May 04
MIRM: Fair Value Views Turn On 2026 PSC Readout
Analysts have lifted the average price target for Mirum Pharmaceuticals from $106.60 to about $129.73, reflecting updated assumptions on revenue growth, margins and future P/E multiples. Analyst Commentary Recent Street research has been active on Mirum Pharmaceuticals, with several firms revisiting their models and resetting price targets.내러티브 업데이트 • Apr 19
MIRM: 2026 PSC Readout Will Reframe Long Term Earnings Power
Analysts recently lifted Mirum Pharmaceuticals' average price target by several dollars to a range of about $117 to $130, citing updated models that reflect slightly higher revenue growth and profit margin assumptions, along with a modestly higher discount rate and continued focus on upcoming clinical and commercial catalysts. Analyst Commentary Bullish analysts have been steadily lifting their valuation work on Mirum Pharmaceuticals, pushing price targets into a band that runs roughly from the high $110s to about $130.내러티브 업데이트 • Apr 05
MIRM: 2026 PSC Readout And Guidance Will Reset Earnings Power Narrative
Analysts have lifted their average price targets on Mirum Pharmaceuticals by several dollars into a range that now runs into the low to mid $100s, citing updated models that incorporate higher revenue growth, stronger profit margins and still elevated but slightly lower future P/E assumptions. Analyst Commentary Recent research has leaned clearly positive on Mirum Pharmaceuticals, with several bullish analysts lifting price targets into a clustered range around the low to mid US$100s.내러티브 업데이트 • Mar 22
MIRM: 2026 Clinical Readouts And Guidance Will Reframe Earnings Power Narrative
Analysts have lifted their average price targets on Mirum Pharmaceuticals into a roughly $117 to $130 range, citing in line reported revenue, reiterated guidance, continued commercial traction in Livmarli and the bile acid portfolio, as well as upcoming clinical catalysts as key supports for the updated views. Analyst Commentary Recent Street research on Mirum Pharmaceuticals has leaned positive, with multiple bullish analysts revisiting their models and adjusting price targets in a tight cluster around the low to mid $120s.내러티브 업데이트 • Mar 07
MIRM: 2026 Pipeline Catalysts And Guidance Will Reshape Earnings Power Narrative
Analysts have lifted their aggregate price targets for Mirum Pharmaceuticals by several dollars into a roughly $117 to $130 range, reflecting updated views on revenue potential, margin expectations and future P/E multiples following recent earnings, guidance and pipeline commentary. Analyst Commentary Recent Street research has tilted clearly positive, with a cluster of bullish analysts lifting their targets into the low to mid US$100s after Mirum's latest earnings, guidance and pipeline updates.
내러티브 업데이트 • Feb 21
MIRM: Elevated Expectations Will Hinge On Upcoming PSC Trial Outcome
Analysts have lifted their fair value estimate for Mirum Pharmaceuticals to $95.00 from $56.92, citing higher modeled revenue growth, improved profit margin assumptions, and reinforced confidence in Livmarli and the broader bile acid portfolio, following recent price target increases and new Outperform initiations across the Street. Analyst Commentary Recent Street research around Mirum Pharmaceuticals has centered on the commercial trajectory for Livmarli, the broader bile acid portfolio, and upcoming clinical milestones.내러티브 업데이트 • Feb 07
MIRM: Busy 2026 Pipeline And Guidance Will Reframe Execution Expectations
Narrative Update on Mirum Pharmaceuticals The analyst price target for Mirum Pharmaceuticals has moved from US$89 to US$140. Analysts cite higher modeled fair value, despite adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions following recent price target increases across several research firms.분석 기사 • Jan 28
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%
Despite an already strong run, Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) shares have been powering on, with a gain of...내러티브 업데이트 • Jan 23
MIRM: Fair Value Tied To 2026 PSC Data And Execution Risks
Analysts have nudged their fair value estimate for Mirum Pharmaceuticals higher from $103.10 to $106.60, citing recently raised Street price targets that reflect stronger than expected preliminary results, updated guidance, and continued confidence around Livmarli and the late stage pipeline. Analyst Commentary Street research on Mirum Pharmaceuticals has centered on the recent preliminary results, guidance, and the outlook for Livmarli and the late stage pipeline, with several firms updating their models and fair value assumptions.내러티브 업데이트 • Jan 08
MIRM: Shares Should Benefit From 2026 PSC Volixibat Data Trigger
Narrative Update The analyst price target for Mirum Pharmaceuticals has been raised to $95, up from $81. Analysts point to Livmarli's recent sales performance and upcoming late stage volixibat readouts in primary sclerosing cholangitis and primary biliary cholangitis as key drivers of their updated views.내러티브 업데이트 • Dec 25
MIRM: Shares Should Climb On 2026 PSC Volixibat Pivotal Readout
Analysts have raised their price target on Mirum Pharmaceuticals to $103.10 from $95.20, citing Livmarli's sustained commercial traction and the potential for volixibat's late stage data to drive the next phase of growth toward profitability. Analyst Commentary Recent research updates reflect a generally constructive stance on Mirum Pharmaceuticals, with price targets moving higher as Livmarli execution remains solid and expectations build around the volixibat pipeline.내러티브 업데이트 • Dec 11
MIRM: Shares Will Rise On 2026 Pivotal PSC Volixibat Readout
Mirum Pharmaceuticals' analyst price target has been lifted from $87.99 to $95.20 as analysts highlight Livmarli's strong commercial trajectory, an improving path to profitability, and the potential next wave of growth from late stage volixibat data expected in 2026. Analyst Commentary Bullish analysts see the latest price target increases as a reflection of Mirum's strengthening commercial execution and expanding pipeline visibility.내러티브 업데이트 • Nov 27
MIRM: Shares Will Surge On Pivotal Late-Stage Data Readout In 2026
Mirum Pharmaceuticals' analyst price target has increased from $86.09 to $87.99. This reflects analysts' optimism about continued strong sales, upcoming clinical milestones, and anticipated profitability improvements.내러티브 업데이트 • Nov 13
MIRM: Shares Will Rally On Pivotal Clinical Data Expected In 2026
Analysts have raised their price target for Mirum Pharmaceuticals from $83.55 to $86.09 per share, citing continued strong performance for Livmarli and optimism around late-stage clinical catalysts expected over the next two years. Analyst Commentary Recent research updates reflect a broadly positive outlook for Mirum Pharmaceuticals, with several analysts raising their price targets and emphasizing key growth drivers for the company.내러티브 업데이트 • Oct 30
Upcoming Clinical Milestones Will Drive Rare Disease Pipeline Expansion Into 2026
Mirum Pharmaceuticals' analyst price target has been raised, with the fair value estimate increasing slightly to $83.55 from $83. Analysts cite continued strong Livmarli performance and upcoming clinical milestones as key factors supporting this upward revision.분석 기사 • Oct 16
Mirum Pharmaceuticals (NASDAQ:MIRM) Is Carrying A Fair Bit Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...내러티브 업데이트 • Oct 15
Genetic Testing And International Expansion Will Broaden Rare Disease Markets
Analysts have raised their fair value price target for Mirum Pharmaceuticals from $81 to $83, citing higher revenue growth forecasts and strong performance in recent quarters. Analyst Commentary Analysts have expressed a largely positive view on Mirum Pharmaceuticals' outlook, citing several drivers of growth and ongoing execution.내러티브 업데이트 • Sep 25
Genetic Testing And International Expansion Will Broaden Rare Disease Markets
Analysts raised Mirum Pharmaceuticals’ price target from $78.27 to $81.00, citing surging Livmarli sales, strong Q2 results, a robust and expanding rare disease pipeline, and continued commercial execution. Analyst Commentary Bullish analysts meaningfully increased Livmarli sales forecasts following Mirum's strong Q2 earnings beat and upwardly revised 2025 guidance.분석 기사 • Aug 11
Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates
Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) shareholders will have a reason to smile today, with the analysts making...내러티브 업데이트 • Aug 08
Genetic Testing And International Expansion Will Broaden Rare Disease Markets
Mirum Pharmaceuticals’ modest target price increase reflects improved consensus revenue growth forecasts, though this is partially offset by a slight expansion in the future P/E multiple, resulting in a marginal upward revision of the fair value to $77.20. What's in the News Mirum Pharmaceuticals raised its 2025 revenue guidance to $490 million to $510 million.새로운 내러티브 • May 09
FDA And Japanese Approvals Will Open New Markets
Strong revenue growth and recent regulatory approvals are set to expand market reach and positively impact future revenues.Seeking Alpha • Mar 24
Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like
Summary Mirum Pharmaceuticals, Inc.'s stock has risen over 50% in the past year, despite a recent 15% dip due to market volatility. The company reported strong Q4 results in late February with a 43% Y/Y revenue increase, driven by Livmarli's sales growth. Analysts unanimously rate Mirum as a Buy and expect significant revenue growth and reduced losses. The company should be cash flow positive by the end of this fiscal year. Mirum's pipeline includes promising candidates like Volixibat and MRM-3379, both with billion-dollar potential, supporting a positive long-term outlook. An updated analysis around MIRM stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Summary The biotech industry is primed for increased M&A activity due to low valuations and big pharma's need to offset patent losses. Mirum Pharmaceuticals, with three approved drugs and a strong pipeline, is a possible prime takeover candidate with significant growth potential. MIRM's stock shows strong upward momentum, supported by impressive sales growth, positive cash flow, and a clear path to profitability. Wall Street is bullish on MIRM, projecting a 50% upside to $63. We are slightly (a lot) more bullish right now at $64.40 (two years from now at $82.40). Read the full article on Seeking AlphaSeeking Alpha • Dec 25
Mirum Pharma: Buy At Dips For Volixibat Potential
Summary Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 years away from approval, but supported in the interim by the other approved drugs. Financially, Mirum has a market cap of $2bn, a cash balance of $294mn, and a cash runway of over 12-15 quarters. The key risk lies in the intense competition in the PBC space and the wait for volixibat's approval. Despite trading at the higher end of its 52-week range, Mirum is an attractive buy on dips. Read the full article on Seeking AlphaSeeking Alpha • Oct 04
Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Summary Mirum Pharmaceuticals, Inc.'s stock has risen >150% since 2021, driven by its rare disease treatments, but its current valuation may be overstated given ongoing losses and competitive pressures. The company's key revenue drivers include Livmarli, Cholbam, and Chenodal, with potential peak revenues of around $450M, but profitability remains elusive. Volixibat shows promise in Phase 2b trials for PSC and PBC, but approval is unlikely before 2027, and competition is intense. Mirum's cash burn and lengthy approval timelines suggest a potential downward price correction, with a lower valuation likely in 2025. Read the full article on Seeking AlphaSeeking Alpha • Jul 17
Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Summary Mirum Pharmaceuticals develops therapies for rare liver diseases, focusing on bile acid regulation. Key products include Livmarli, Cholbam, and Chenodal, with Chenodal recently completing Phase 3 trials for CTX. MIRM's pipeline also has Volixibat in Phase 2b trials for PSC and PBC. MIRM's recent acquisition of Cholbam and Chenodal from Travere Therapeutics is strategically significant. I believe that despite trading at a premium, MIRM's growth prospects and strong fundamentals justify a "buy" rating. Read the full article on Seeking AlphaSeeking Alpha • Apr 22
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Summary The FDA approved Mirum Pharmaceuticals, Inc.'s Limvarli for treatment of cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis; Potential for further label expansion in younger patients possible due to positive MARCH study. Interim results from VANTAGE study using Volixibat for patients with PBC are expected 1st half of 2024; The global primary biliary cholangitis therapeutics market is projected to reach $1.4 billion by 2032. Interim results from VISTAS study using Volixibat for patients with PSC expected 1st half 2024; The global Primary Sclerosing Cholangitis market is expected to reach $586.8 million by 2034. Total net product revenues of $178.9 million for the full-year ending December 2023, compared to the prior year ending December 2022 with net product revenues of only $75.1 million in sales. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Mirum Pharmaceuticals: Advancing On Several Key Fronts
Summary Mirum Pharmaceuticals delivered solid Q4 results last week, with projected sales growth of around 70% for fiscal year 2024. The company's primary growth driver is Livmarli, an oral solution approved for the treatment of cholestatic pruritus for Alagille syndrome patients. MIRM has other promising compounds in its pipeline, including Volixibat, and is projected to become profitable in FY2025. An updated analysis around Mirum Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha매출 및 비용 세부 내역
매출 및 비용 세부 내역
Mirum Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 570 | -799 | 296 | 243 |
| 31 Dec 25 | 521 | -23 | 257 | 186 |
| 30 Sep 25 | 472 | -41 | 240 | 174 |
| 30 Jun 25 | 429 | -59 | 228 | 163 |
| 31 Mar 25 | 379 | -77 | 214 | 149 |
| 31 Dec 24 | 337 | -88 | 202 | 141 |
| 30 Sep 24 | 307 | -100 | 192 | 128 |
| 30 Jun 24 | 264 | -109 | 178 | 122 |
| 31 Mar 24 | 224 | -159 | 161 | 111 |
| 31 Dec 23 | 186 | -163 | 146 | 103 |
| 30 Sep 23 | 145 | -164 | 126 | 103 |
| 30 Jun 23 | 116 | -176 | 112 | 103 |
| 31 Mar 23 | 96 | -129 | 100 | 106 |
| 31 Dec 22 | 77 | -136 | 89 | 107 |
| 30 Sep 22 | 52 | -42 | 82 | 104 |
| 30 Jun 22 | 39 | -53 | 76 | 108 |
| 31 Mar 22 | 32 | -70 | 69 | 117 |
| 31 Dec 21 | 19 | -84 | 59 | 131 |
| 30 Sep 21 | 16 | -179 | 47 | 133 |
| 30 Jun 21 | 11 | -153 | 36 | 119 |
| 31 Mar 21 | 0 | -132 | 27 | 102 |
| 31 Dec 20 | 0 | -103 | 23 | 82 |
| 30 Sep 20 | 0 | -84 | 20 | 66 |
| 30 Jun 20 | 0 | -78 | 18 | 62 |
| 31 Mar 20 | 0 | -68 | 15 | 55 |
| 31 Dec 19 | 0 | -53 | 12 | 43 |
| 30 Sep 19 | 0 | -61 | 8 | 32 |
양질의 수익: MIRM 은(는) 현재 수익성이 없습니다.
이익 마진 증가: MIRM는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: MIRM은 수익성이 없으며 지난 5년 동안 손실이 연평균 17.2% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 MIRM의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: MIRM은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: MIRM는 현재 수익성이 없으므로 자본 수익률이 음수(-329.43%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 14:08 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Mirum Pharmaceuticals, Inc.는 23명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |